https://www.bioworld.com/rss en-us Chinese peptide therapeutics developer Shaanxi Micot Pharmaceutical Technology Co. Ltd. is seeking up to HK$1.22 billion (US$155 million) in a Hong Kong IPO to advance its lead phase III chronic kidney disease candidate, MT-1013, and next-generation obesity therapies. http://www.bioworld.com/articles/731909 Wed, 17 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731909-chinas-micot-targets-hk12b-ipo-to-advance-metabolic-portfolio IPO, coins, upward arrow In a little more than a month, 17 big biopharma companies will be subject to U.S. President Donald Trump’s long-promised section 232 global biopharma sector tariff. But instead of paying the 100% duty on imported patented drugs and their key ingredients, most of those companies, if not all, will pay much reduced rates or no tariff at all, based on where the imports are coming from, what type of drug is being imported, and whether the companies have signed onshoring and most-favored-nation pricing agreements with the administration. http://www.bioworld.com/articles/731904 Wed, 17 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731904-rx-tariff-just-around-the-corner Prescription bottle with dollar sign shadow Laekna Inc. is handing ex-China rights to internally discovered PI3Kα pan-mutant selective inhibitor LAE-118 to U.S.-based Vasque Bio Inc. in a deal worth up to $527 million, marking another asset-monetization move by the Shanghai company as it looks to fund and accelerate development across its oncology and metabolic disease pipeline. http://www.bioworld.com/articles/731987 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731987-laekna-licenses-lae-118-ex-china-to-vasque-in-527m-deal Deal handshake with graphic overlay Oricell Therapeutics Holdings Ltd.’s glypican-3 (GPC3)-targeted autologous CAR T therapy, Ori-C101, is heading into a confirmatory registration phase II trial in patients with GPC3-positive advanced hepatocellular carcinoma, positioning it as the first GPC3-directed immune cell therapy – and the first CAR T therapy for liver cancer – to reach that stage of development. http://www.bioworld.com/articles/731986 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731986-oricell-brings-first-pivotal-stage-car-t-in-liver-cancer Liver anatomy Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant colony-stimulating factor 1 receptor inhibitor, with plans to move the asset into a biomarker-based and placebo-controlled study. http://www.bioworld.com/articles/731984 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731984-elixirons-enrupatinib-shows-upbeat-interim-phase-ii-ad-results Illustration of amyloid plaques in Alzheimer's disease Chinese diabetes specialist Gan & Lee Pharmaceuticals is strengthening its position in metabolic disease after reporting positive phase III data for both once-weekly basal insulin candidate Ludefen and obesity therapy bofanglutide. http://www.bioworld.com/articles/731983 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731983-chinese-challenger-gan-and-lee-gains-momentum-in-metabolic-disease Blood glucose chart and monitor, stethoscope, injector pen Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its pipeline and geographic reach across Asia Pacific. http://www.bioworld.com/articles/731982 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731982-three-deals-in-six-days-everest-builds-late-stage-apac-portfolio Hands holding gears Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout of moderate to severe plaque psoriasis. http://www.bioworld.com/articles/731981 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731981-takedas-zasocitinib-bests-sotyktu-in-phase-iii-psoriasis-trial Dermatology exam After raising HK$1.255 billion (US$160 million) in its IPO on the Hong Kong Stock Exchange earlier this month, Longbio Pharma Co. Ltd.’s lead candidate, LP-003, met the primary endpoint of total nasal symptom scores during peak pollen season in moderate to severe seasonal allergic rhinitis. http://www.bioworld.com/articles/731980 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731980-longbios-lp-003-meets-phase-iii-allergy-endpoints Woman holding tissue to nose with plants, pollen China’s National Medical Products Administration has approved Suzhou Alphamab Co. Ltd.’s HER2 bispecific antibody, anbenitamab (KN-026), through priority review for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received at least one trastuzumab-containing regimen. http://www.bioworld.com/articles/731979 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731979-china-clears-alphamabs-her2-bispecific-antibody-in-gastric-cancer Stomach cross-section on scientific background Dimerix Ltd. has signed an exclusive licensing deal with Everest Medicines Ltd. to commercialize its phase III kidney disease candidate DMX-200 in a transaction worth up to AU$481 million (US$340 million), plus sales royalties. http://www.bioworld.com/articles/731893 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731893-dimerix-out-licenses-dmx-200-to-everest-in-au481m-deal Kidneys After raising HK$1.255 billion (US$160 million) in its IPO on the Hong Kong Stock Exchange earlier this month, Longbio Pharma Co. Ltd.’s lead candidate, LP-003, met the primary endpoint of total nasal symptom scores during peak pollen season in moderate to severe seasonal allergic rhinitis. http://www.bioworld.com/articles/731878 Mon, 15 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731878-longbios-lp-003-meets-phase-iii-allergy-endpoints Woman holding tissue to nose with plants, pollen Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant colony-stimulating factor 1 receptor inhibitor, with plans to move the asset into a biomarker-based and placebo-controlled study. http://www.bioworld.com/articles/731877 Mon, 15 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731877-elixirons-enrupatinib-shows-upbeat-interim-phase-ii-ad-results Illustration of amyloid plaques in Alzheimer's disease Chinese diabetes specialist Gan & Lee Pharmaceuticals is strengthening its position in metabolic disease after reporting positive phase III data for both once-weekly basal insulin candidate Ludefen and obesity therapy bofanglutide. http://www.bioworld.com/articles/731876 Mon, 15 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731876-chinese-challenger-gan-and-lee-gains-momentum-in-metabolic-disease Blood glucose chart and monitor, stethoscope, injector pen Oricell Therapeutics Holdings Ltd.’s glypican-3 (GPC3)-targeted autologous CAR T therapy, Ori-C101, is heading into a confirmatory registration phase II trial in patients with GPC3-positive advanced hepatocellular carcinoma, positioning it as the first GPC3-directed immune cell therapy – and the first CAR T therapy for liver cancer – to reach that stage of development. http://www.bioworld.com/articles/731817 Fri, 12 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731817-oricell-brings-first-pivotal-stage-car-t-in-liver-cancer Liver anatomy Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout of moderate to severe plaque psoriasis. http://www.bioworld.com/articles/731816 Fri, 12 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731816-takedas-zasocitinib-bests-sotyktu-in-phase-iii-psoriasis-trial Dermatology exam Laekna Inc. is handing ex-China rights to internally discovered PI3Kα pan-mutant selective inhibitor LAE-118 to U.S.-based Vasque Bio Inc. in a deal worth up to $527 million, marking another asset-monetization move by the Shanghai company as it looks to fund and accelerate development across its oncology and metabolic disease pipeline. http://www.bioworld.com/articles/731802 Thu, 11 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731802-laekna-licenses-lae-118-ex-china-to-vasque-in-527m-deal Deal handshake with graphic overlay China’s National Medical Products Administration has approved Suzhou Alphamab Co. Ltd.’s HER2 bispecific antibody, anbenitamab (KN-026), through priority review for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received at least one trastuzumab-containing regimen. http://www.bioworld.com/articles/731801 Thu, 11 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731801-china-clears-alphamabs-her2-bispecific-antibody-in-gastric-cancer Stomach cross-section on scientific background Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its pipeline and geographic reach across Asia Pacific. http://www.bioworld.com/articles/731721 Wed, 10 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731721-three-deals-in-six-days-everest-builds-late-stage-apac-portfolio Hands holding gears Total biopharma financing through the first five months of 2026 reached $49.46 billion, the third-highest total for the period in the dataset and more than doubling of 2025’s $21.4 billion over the same stretch. http://www.bioworld.com/articles/731832 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731832-hemab-soars-89-on-debut-as-biopharma-ipos-stay-strong-in-may Gray and green glass dollar symbols with arrow pointing up After a major breach of trust when its data were advertised for sale in China, the UK Biobank will now attempt to recall data previously downloaded by legitimate researchers and seek assurances information has been deleted from local servers. http://www.bioworld.com/articles/731831 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731831-uk-biobank-seeks-to-recall-downloads-after-health-data-breach Data breach - red broken padlock Innovent Biologics Co. Ltd.’s Claudin18.2-targeted antibody-drug conjugate (ADC), arcotatug tavatecan (IBI-343, TAK-921), met the primary endpoint in the international multicenter phase III G-Hope-001 trial in advanced gastric cancer, according to interim results. http://www.bioworld.com/articles/731830 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731830-innovent-submits-nda-for-cldn182-adc-for-gastric-cancer Gastric cancer If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base. http://www.bioworld.com/articles/731829 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731829-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins China compass Agios Pharmaceuticals Inc.’s potential $665 million deal for Oscotec Inc.’s cevidoplenib, a phase III-ready oral SYK inhibitor to treat immune thrombocytopenia, marks a new chapter of development focused on cancer therapy resistance for Oscotec, CEO Yoon Tae-young said. http://www.bioworld.com/articles/731828 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731828-disciplined-665m-deal-moves-oscotecs-cevidoplenib-to-agios Deal handshake with coin, chart background The recent introduction of the bipartisan Biotech Investment National Security Act in the U.S. House has industry and venture capitalists urging lawmakers to take a breath, step back, and consider a less invasive approach than restricting U.S. biopharma deals with Chinese innovators. http://www.bioworld.com/articles/731827 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731827-competitive-approach-better-than-restricting-deals-with-china China U.S. handshake China’s National Medical Products Administration (NMPA) on June 4 granted conditional approvals to two oncology drugs from Lupeng Pharmaceutical Co. Ltd. and Vcare Pharmatech Co. Ltd., as well as one hemophilia drug developed by Staidson Biopharmaceutical Co. Ltd. http://www.bioworld.com/articles/731712 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731712-nmpa-gives-conditional-nods-to-drugs-by-lupeng-vcare-staidson Red wooden approved stamp Japan has granted marketing approval to Oncolys Biopharma Inc.’s oncolytic adenovirus product, Telomelysin (suratadenoturev, OBP-301), for treating esophageal cancer in patients who are not eligible for curative resection or chemoradiotherapy. The approval marks the first oncolytic adenovirus product approved for esophageal cancer. http://www.bioworld.com/articles/731711 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731711-japan-backs-oncolys-virus-therapy-for-esophageal-cancer Illustration of cancer on the esophagus Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military company,” which makes it a “biotechnology company of concern” under the Biosecure Act. “Such designation is mistaken and baseless,” the global contract research, development and manufacturing organization said in an open letter to its life sciences partners. “We will pursue every available avenue to correct this mistake.” That includes appealing the designation. http://www.bioworld.com/articles/731710 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731710-wuxi-apptec-insists-its-not-a-chinese-military-company Wuxi Apptec signage Credit: Wuxi Apptec The recent introduction of the bipartisan Biotech Investment National Security Act in the U.S. House has industry and venture capitalists urging lawmakers to take a breath, step back, and consider a less invasive approach than restricting U.S. biopharma deals with Chinese innovators. http://www.bioworld.com/articles/731692 Mon, 08 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731692-competitive-approach-better-than-restricting-deals-with-china China U.S. handshake If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base. http://www.bioworld.com/articles/731634 Fri, 05 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731634-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins China compass